Veracyte VCYT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $88.01M+166% | $66.35M+175% | $30.32M+427% | $26.34M+149% | $33.05M+148% | ||
| $21.48M-7.5% | $21.42M-8.7% | $22.37M-5.0% | $22.98M-8.0% | $23.23M-11.0% | ||
| $45.4M+15.9% | $43.6M+20.3% | $42.33M+24.0% | $40.32M+23.5% | $39.19M+18.1% | ||
| —— | —— | —— | -$149K+26.6% | -$172K+4.4% | ||
| —— | —— | —— | —— | —— | ||
| -$5.57M-228% | -$1.04M+75.9% | -$1.9M+41.8% | $514K— | $4.36M— | ||
| -$271K— | -$525K— | —— | —— | —— | ||
| -$2.22M-107% | -$2.48M-108% | $31.52M+726% | $30.53M+752% | $29.75M+771% | ||
| -$13.86M-6,762% | -$15.46M-813% | -$1.95M— | -$1.58M— | $208K— | ||
| $166.16M+85.8% | $136.31M+81.5% | $108.25M+63.7% | $93.45M+85.7% | $89.42M+139% | ||
| $10.82M-1.4% | $9.68M-14.3% | $10.04M+4.1% | $9.49M-7.0% | $10.97M-1.2% | ||
| $225M+125% | $150M+200% | $150M— | $150M— | $100M— | ||
| —— | —— | —— | -$108.43M— | -$110.97M— | ||
| $13.85M-30.7% | $14.08M-29.6% | $13.84M-25.2% | $20.51M+139% | $19.99M+133% | ||
| $18.22M+12.4% | $18.3M+72.9% | $17.92M+112% | $17.29M+98.5% | $16.21M+95.4% | ||
| —— | —— | —— | —— | —— | ||
| $587K— | $719K— | $306K— | —— | —— | ||
| $77.03M— | $123.6M— | —— | —— | —— | ||
| —— | —— | $3.42M+109% | $3.77M+120% | $2.36M— | ||
| —— | —— | —— | —— | —— | ||
| -$13.86M-6,762% | -$15.46M-813% | -$1.95M— | -$1.58M— | $208K— | ||
| —— | —— | —— | $3.84M+11,524% | $112K-61.6% | ||
| —— | —— | —— | —— | $4M— | ||
| —— | —— | —— | —— | —— | ||
| -$2.22M-107% | -$2.48M-108% | $31.52M+726% | $30.53M+752% | $29.75M+771% | ||
| —— | —— | $7.86M— | $4.57M— | —— | ||
| $2.82M-40.3% | $2.99M-39.6% | $3.62M-22.3% | $4.27M-4.5% | $4.72M+7.4% | ||
| -$606K-518% | -$581K-149% | -$256K+91.4% | -$182K+95.4% | -$98K+97.5% | ||
| $225M+125% | $150M+200% | $150M— | $150M— | $100M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.85M— | $2.13M— | $1.42M— | $711.25K— | ||
| -$2.22M-107% | -$2.48M-108% | $31.52M+726% | $30.53M+752% | $29.75M+771% | ||
| —— | $0-100% | $1.13M-66.7% | $2.25M0.0% | $3.38M+200% | ||
| $155.34M+98.0% | $126.63M+98.5% | $98.21M+73.9% | $83.97M+109% | $78.45M+198% | ||
| $155.34M+98.0% | $126.63M+98.5% | $98.21M+73.9% | $83.97M+109% | $78.45M+198% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Veracyte's cash flow data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.